Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G-Reference-Cited by-同舟云学术

Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G

Published:2022-10 Issue:42 Volume:40 Page:6093-6099
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Stanfield Brent A.,Bravo Fernando J.,Dixon David A.,Chouljenko Vladimir N.,Kousoulas Konstantin G.,Bernstein David I.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference32 articles.

1. Herpes simplex virus: global infection prevalence and incidence estimates, 2016;James;Bull World Health Organ,2020

2. Herpes simplex vaccines: prospects of live-attenuated HSV vaccines to combat genital and ocular infections;Stanfield;Curr Clin Microbiol Rep,2015

3. Rational design of live-attenuated vaccines against herpes simplex viruses;Stanfield;Viruses,2021

4. Centers for Disease C, Prevention. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. MMWR Morb Mortal Wkly Rep. 2010;59(15):456-9.

5. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies;Freeman;AIDS,2006

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Alpha Herpes Viruses Vaccines for Human;Vaccines;2023-06-12

2. Inactivation of the UL37 Deamidase Enhances Virus Replication and Spread of the HSV-1(VC2) Oncolytic Vaccine Strain and Secretion of GM-CSF;Viruses;2023-01-27